Genentech Inc., of South San Francisco, a unit of Roche AG, reported results from a Phase II study showing that ocrelizumab significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis, as measured by the total number of active brain lesions and relapses

Sunesis Pharmaceuticals Inc., of South San Francisco, began a Phase I trial of its cancer candidate, MLN2480, sponsored by Millennium Pharmaceuticals Inc., of Cambridge, Mass., a unit of Takeda Pharmaceuticals Co

Oxigene Inc., of South San Francisco, presented a retrospective comparative analysis suggesting Zybrestat (fosbretabulin) confers a one-year survival benefit in patients with anaplastic thyroid cancer (ATC) compared to treatment with chemotherapy alone...VistaGen Therapeutics Inc., of South San Francisco, plans to begin its second Phase Ib study of AV-101 for neuropathic pain before the end of the year

Exelixis Inc., of South San Francisco, said the pre-specified number of progression-free survival events required for unblinding data in its pivotal Phase III trial of cabozantinib in medullary thyroid cancer has been reached

Jennerex Inc., of South San Francisco, reported that its liver cancer candidate JX-594, followed by sorafenib (Nexavar), induced tumor responses that were maintained for up to 15 months

Cytokinetics Inc., of South San Francisco, said The Lancet published results from two studies supporting the use of omecamtiv mecarbil in heart failure

Titan Pharmaceuticals Inc., of South San Francisco, reported additional results from its Phase III confirmatory study of Probuphine in opioid dependence, which confirmed the drug's noninferiority to Suboxone (buprenorphine/naloxone

Sunesis Pharmaceuticals Inc., of South San Francisco, published data from a Phase Ib trial of vosaroxin in relapsed or refractory leukemia showing that the drug was well-tolerated and had anti-leukemic activity

Genentech Inc., of South San Francisco, a member of the Roche Group, said the Phase III CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) study met its primary endpoint, showing a statistically significant increase in progression-free survival for patients with HER2-positive metastatic breast cancer who received the combination of pertuzumab and Herceptin (trastuzumab), plus docetaxel chemotherapy vs

Exelixis Inc., of South San Francisco, said that it will report results from its Phase III trial of cabozantinib in medullary cancer (EXAM) by about three months

Titan Pharmaceuticals Inc., of South San Francisco, said discussions with the FDA regarding the confirmatory Phase III study of opioid dependence drug Probuphine have led Titan to add a primary endpoint measurement of patient-reported illicit opioid use in addition to the measurement of urine samples

Cytokinetics Inc., of South San Francisco, opened enrollment in a second Phase II trial of CK-2017357, a fast skeletal troponin activator, in patients with amyotrophic lateral sclerosis

Titan Pharmaceuticals Inc., of South San Francisco, received a letter from the FDA providing comments on the revised statistical analysis plan (SAP) for a confirmatory Phase III study of Probuphine in patients with opioid dependence

KAI Pharmaceuticals Inc., of South San Francisco, presented preclinical and clinical data showing its lead candidate KAI-4169 holds promise as a treatment for chronic kidney disease-mineral and bone disorder (CKD-MBD

Cytokinetics Inc., of South San Francisco, Calif., completed a Phase IIa trial of its skeletal muscle activator, CK-2017357, in peripheral artery disease

Exelixis Inc., of South San Francisco, said data from a Phase I trial of cabozantinib in patients with advanced solid tumors in lymphoma were published in the Journal of Clinical Oncology

Oxigene Inc., of South San Francisco, announced that investigators at the University of Florida initiated a Phase I study of OXi4503 for the treatment of patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS

Cytokinetics Inc., of South San Francisco, opened enrollment in its Phase IIb trial testing an intravenous formulation of omecamtiv mecarbil, a cardiac muscle myosin activator

Cytokinetics Inc., of South San Francisco, said additional Phase IIa data of CK-2017357 in patients with amyotrophic lateral sclerosis showed that, at 24 hours after each of the 250-mg and 500-mg doses, dose-related increases in the change from the day one baseline in percent predicted muscle strength achieved nominal statistical significance for elbow flexion (p = 0.005 and 0.0004, respectively